Lifestyle Asset Management Inc. lifted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 422.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 71,488 shares of the company's stock after purchasing an additional 57,799 shares during the quarter. Lifestyle Asset Management Inc.'s holdings in Dr. Reddy's Laboratories were worth $1,129,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. World Investment Advisors LLC bought a new position in shares of Dr. Reddy's Laboratories during the third quarter valued at approximately $3,459,000. Nordea Investment Management AB raised its holdings in Dr. Reddy's Laboratories by 441.8% in the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company's stock worth $1,992,000 after purchasing an additional 102,226 shares in the last quarter. GAMMA Investing LLC lifted its position in Dr. Reddy's Laboratories by 369.9% during the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company's stock valued at $107,000 after acquiring an additional 5,352 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 109.3% during the 3rd quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock valued at $1,053,000 after purchasing an additional 6,920 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Dr. Reddy's Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock valued at $76,455,000 after buying an additional 114,294 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on RDY shares. Nomura downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. StockNews.com cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Finally, Barclays cut their price target on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th.
View Our Latest Analysis on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Price Performance
NYSE:RDY traded down $0.14 during trading hours on Friday, hitting $14.02. 1,781,386 shares of the stock were exchanged, compared to its average volume of 2,268,659. The firm's fifty day moving average price is $14.87 and its 200 day moving average price is $15.53. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. The company has a market cap of $11.70 billion, a P/E ratio of 22.39 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a 52-week low of $13.61 and a 52-week high of $16.89.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.81% and a return on equity of 18.53%. As a group, equities research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.81 EPS for the current fiscal year.
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
See Also
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
